

Breast Cancer

Breast cancer survival depends on catching it early and knowing the exact type, because each type responds to different treatments.

THE STORY IN ONE SENTENCE

Breast cancer survival depends on catching it early and knowing the exact type, because each type responds to different treatments.

"A lump in the breast that doesn't hurt is the first clue—find it early, figure out the type (hormone-fed, HER2-driven, or triple-negative), and pick the right treatment, because the type decides if the patient lives."

Normal anatomy — the body's job

The breast is a gland made of lobules (milk-making sacs), ducts (tubes that carry milk to the nipple), fat, and connective tissue. Hormones like estrogen and progesterone control when breast cells grow and when they rest. Normally, old cells die and new ones replace them in an orderly, controlled way.

BODY'S JOB

The breast's job is to make and deliver milk to feed a baby. Outside of pregnancy and breastfeeding, the tissue stays quiet, waiting for hormone signals. Estrogen tells the ducts to grow; progesterone tells the lobules to get ready to make milk. When those hormones drop (like after menopause), the breast tissue shrinks and gets fattier.

1. Lobules (tiny grape-like clusters) make milk when hormones say "go."
2. Ducts (thin tubes) carry that milk from the lobules to the nipple.
3. Estrogen and progesterone rise and fall with your cycle, telling breast cells when to grow and when to rest.
4. Lymph vessels drain fluid from the breast into lymph nodes under the arm, filtering out germs and old cells.
5. Blood vessels bring oxygen and nutrients to keep the tissue healthy.

What breaks

One cell in the breast starts copying itself over and over without stopping, ignoring all the normal "stop" signals. That runaway copying forms a lump. The cell's DNA has damage—either from aging, inherited mutations (like BRCA1 or BRCA2), or bad luck—and it loses the ability to repair itself or die when it should.

CLINICAL TERM

Breast cancer begins when a single epithelial cell (usually in a duct or lobule) acquires mutations that turn off tumor suppressor genes (like TP53, BRCA1, BRCA2) and turn on oncogenes (like HER2/ERBB2, PIK3CA, or cyclin D1). The cell escapes apoptosis (programmed cell death) and ignores contact inhibition, so it keeps dividing. The tumor is classified by three key drivers: estrogen receptor (ER), progesterone receptor (PR), and HER2. ER/PR-positive cancers are fed by hormones. HER2-positive cancers are driven by overexpression of the HER2 protein. Triple-negative cancers lack all three receptors and are harder to treat because they don't respond to hormone therapy or HER2-targeted drugs.

How the body compensates

At first, the body doesn't know anything is wrong—the lump grows silently, and vital signs stay normal. The immune system tries to wall off the tumor by sending lymphocytes and macrophages, but cancer cells evolve tricks to hide from immune attack. The danger is that the patient feels fine while the tumor spreads through lymph or blood to distant organs. By the time symptoms appear (bone pain, trouble breathing, yellowing of the skin and eyes (jaundice)), the cancer is often Stage IV and much harder to cure.

1. Early on, the tumor is tiny (Stage 0 or I), stuck in the duct or lobule (carcinoma in situ) or just barely invasive. The patient feels nothing, and vital signs are normal.
2. The immune system notices abnormal cells and sends T-cells and natural killer cells to destroy them. Some cancers are killed this way and never cause trouble (immune surveillance).
3. But successful cancers learn to hide: they turn off markers that say "I'm foreign," or they release signals (like PD-L1) that tell T-cells to stand down. The tumor keeps growing.
4. Lymph nodes under the arm (axillary nodes) trap some cancer cells that escape. The nodes swell as they fill with cancer, but this buys time—it's a firewall before the cancer reaches the bloodstream.
5. Once cancer cells break into blood vessels, they circulate and land in bones (most common), lungs, liver, or brain. These metastases (distant colonies) are what usually kill the patient, not the original breast tumor.

6. Watch for the tipping point: new bone pain (fracture risk), persistent cough or shortness of breath (lung mets), right-upper-quadrant pain or yellowing of the skin and eyes (jaundice) (liver mets), or headache and confusion (brain mets). Once metastatic, breast cancer is treatable but rarely curable.
7. A patient with a small lump and normal labs today can have widespread disease in six months if the tumor is high-grade and triple-negative. Speed matters.
8. Trend over time, not a snapshot: a lump that was 1 cm last month and is 3 cm now is galloping, even if the patient feels fine.

Domino effect

1. A painless, hard lump appears in the breast. — One cell starts dividing out of control and forms a mass. It doesn't hurt because early tumors don't press on nerves—they just push normal tissue aside. The lump feels firm or hard because cancer cells pack tightly and make extra collagen (desmoplastic reaction), unlike soft, normal breast fat.
2. The skin above the lump dimples or puckers (peau d'orange). — As the tumor grows, it invades the Cooper ligaments (fibrous bands that hold the breast shape). Pulling on those ligaments makes the skin dimple inward. If cancer cells clog the lymph channels in the skin, fluid backs up and the skin looks like an orange peel (peau d'orange)—this is inflammatory breast cancer, a fast, aggressive type.
3. The nipple inverts, flattens, or leaks bloody or clear fluid. — Cancer growing in or near the ducts pulls the nipple inward (retraction). If the tumor erodes into a duct, blood or serous fluid leaks out. Paget disease of the nipple (cancer cells in the nipple skin) causes a red, scaly rash that looks like eczema but doesn't heal.
4. Lymph nodes under the arm swell and feel firm. — Cancer cells travel through lymph vessels into the axillary (armpit) lymph nodes. The nodes swell as they fill with cancer, trying to trap it before it spreads further. A swollen, hard, fixed (stuck-in-place) node is a red flag that cancer has left the breast.
5. Bone pain or a fracture happens without much trauma (pathologic fracture). — Cancer cells that reach the bones (usually spine, ribs, pelvis, femur) release signals that wake up osteoclasts (bone-eating cells). The osteoclasts dissolve bone to release calcium, which the cancer uses to grow. The bone becomes weak and brittle, so it breaks from normal activity. High calcium in the blood (hypercalcemia) makes the patient tired, confused, and constipated.
6. Shortness of breath or a dry cough that won't go away. — Cancer cells lodge in the tiny blood vessels of the lungs and grow into nodules. These nodules crowd out normal lung tissue, so less oxygen gets into the blood. Fluid can build up around the lung (malignant pleural a fluid collection (effusion)), pressing on the lung and making it collapse partially.

7. Right-sided belly pain, yellowing of the skin and eyes (jaundice) (yellow skin and eyes), or confusion. — Cancer spreads to the liver through the bloodstream. Liver metastases block bile ducts, so bilirubin (a yellow waste product) backs up into the blood, turning the skin and eyes yellow. The liver can't clean toxins from the blood, so ammonia builds up and causes confusion (hepatic encephalopathy). Loss of liver function is often fatal.
8. Headache, seizures, weakness on one side, or personality changes. — Cancer cells cross the blood-brain barrier and grow in the brain. Brain metastases press on brain tissue, causing swelling (edema) and high pressure inside the skull. Depending on the location, the patient may have headaches, seizures, one-sided weakness, vision problems, or changes in thinking and behavior. Brain mets are a late, life-threatening complication.

Symptoms · what the patient feels, and why

- A new lump or thickening in one breast or underarm: Cancer cells grow in a clump and form a mass that feels different from normal breast tissue. The lump is often hard, has uneven edges, and does not move easily when you push it.
- One breast becomes larger or changes shape: The tumor takes up space and pulls on nearby tissue, making the breast look different in size or shape. Swelling can also happen if cancer blocks lymph vessels (tiny tubes that drain fluid away).
- Dimpling, puckering, or skin that looks like an orange peel: Cancer cells pull on the ligaments (stretchy bands) that hold the breast skin in place, making the skin pull inward or look bumpy. When lymph fluid cannot drain, the skin may swell and the pores become obvious, like the surface of an orange.
- Nipple turns inward or changes position: The tumor pulls on the ducts (tiny milk tubes) or other tissue behind the nipple, causing the nipple to retract (pull back inside) or point in a new direction.
- Clear or bloody fluid leaking from the nipple without squeezing: Cancer growing inside a duct can break open tiny blood vessels or make cells produce abnormal fluid that leaks out on its own. Normal discharge is usually milky or clear and only comes when you squeeze.
- Redness, scaliness, or thickening of the nipple or breast skin: Some breast cancers (like inflammatory breast cancer) block the lymph vessels in the skin, causing swelling, redness, and warmth—like an infection but without fever. Other cancers (like Paget disease) grow in the nipple skin itself, making it red, crusty, or scaly.
- Pain or tenderness in one breast (less common but possible): Most breast cancers do not hurt at first. When pain does happen, the tumor may be pressing on nerves or the breast tissue may be swollen and stretched. Pain alone is rarely cancer, but a painful lump that does not go away needs to be checked.

Focused exam

- New lump in breast tissue, firm, not tender: A painless lump is the most common way breast cancer shows itself. Pain usually means something else, like an infection or a cyst. This lump does not go away with your period or over time.
- Skin dimpling or peau d'orange (skin looks like orange peel): Cancer cells thicken the skin by blocking the tiny lymph channels that drain fluid away. This tells you the cancer is growing into deeper tissue underneath.
- Nipple turned inward or bleeding fluid from nipple: Cancer can pull the tissue behind the nipple inward, or it can block the milk ducts and cause blood or clear fluid to leak out. Either one means cancer is damaging the ducts.
- Swollen lymph nodes under the arm on the same side: Breast tissue drains fluid to the armpit lymph nodes first. Swollen nodes mean cancer cells are traveling there. This changes how we stage and treat the cancer.
- Red rash, swelling, or warmth over the whole breast: This can be inflammatory breast cancer, where cancer cells block the lymph channels in the skin. It looks like an infection but does not get better with antibiotics.
- Bone pain, shortness of breath, or belly swelling: These signs mean cancer has spread beyond the breast to bones, lungs, or liver. This is stage 4 disease and requires a completely different treatment plan.

Diagnostics · every test answers a question

- Diagnostic mammogram (X-ray picture of breast tissue) → Is there a mass, and does it have edges that look smooth (probably benign) or jagged and spiky (worrisome for cancer)?
- Breast ultrasound → Is the lump solid (could be cancer) or filled with fluid (probably a simple cyst)?
- Core needle biopsy of the lump → Are the cells inside this lump cancer, and if so, what type?
- Estrogen receptor (ER), progesterone receptor (PR), and HER2 testing on biopsy tissue → Does this cancer grow in response to hormones (ER/PR positive) or the HER2 protein (HER2 positive)?
- Sentinel lymph node biopsy → Has the cancer spread to the lymph nodes under the arm?
- CT scan of chest, abdomen, and pelvis OR PET scan (if advanced cancer suspected) → Has the cancer spread to distant organs like lungs, liver, or bones?
- Genetic testing for BRCA1 and BRCA2 mutations (if under age 60, triple-negative cancer, or strong family history) → Does the patient carry a gene mutation that raises the risk of more cancers in the future?

Treatment logic

- Lumpectomy (remove lump only) plus radiation OR mastectomy (remove whole breast) → Removes the main tumor before cancer cells multiply and spread. Radiation after lumpectomy kills leftover microscopic cancer cells in the breast tissue that surgery cannot see.
- Sentinel lymph node biopsy or axillary lymph node dissection → Removes lymph nodes under the arm to check if cancer has spread there. Tells us the stage and whether we need more chemotherapy or radiation to the armpit area.
- Hormone therapy: tamoxifen (premenopausal) or aromatase inhibitor like letrozole (postmenopausal) if ER or PR positive → Blocks estrogen from attaching to cancer cells, so they stop getting the signal to grow and divide. Given for 5 to 10 years to prevent the cancer from coming back.
- HER2-targeted therapy: trastuzumab plus pertuzumab, often with chemotherapy, if HER2 positive → Blocks the HER2 protein on cancer cells, cutting off the growth signal that makes them divide quickly. Shrinks aggressive tumors and improves survival.
- Chemotherapy (usually doxorubicin and cyclophosphamide, then paclitaxel) plus pembrolizumab if triple-negative breast cancer → Chemotherapy poisons rapidly dividing cancer cells. Pembrolizumab is an immunotherapy drug that helps the immune system recognize and attack cancer cells.
- PARP inhibitor (olaparib or talazoparib) if BRCA1 or BRCA2 mutation present → Stops cancer cells from repairing breaks in their DNA, forcing them to die. Works especially well in BRCA-mutant cancers because those cells already struggle to fix DNA damage.
- Radiation therapy to the breast (or chest wall after mastectomy) and sometimes lymph node areas → Kills microscopic cancer cells left behind after surgery, reducing the chance the cancer will come back in the same spot.

Medications

Tamoxifen · Selective estrogen receptor modulator (SERM)

Blocks estrogen (a hormone) from attaching to cancer cells in the breast. Many breast cancers grow faster when estrogen sticks to them and sends 'grow' signals. Tamoxifen sits in the estrogen docking spot (receptor) on the cancer cell and blocks the real estrogen from getting in, so the cancer cell doesn't get the 'grow' message.

1. Tamoxifen enters the bloodstream and travels to breast tissue.
2. It finds estrogen receptors (the docking spots) on the surface of hormone-receptor-positive breast cancer cells.
3. Tamoxifen locks onto the receptor, blocking real estrogen from attaching.

4. Without estrogen's 'grow' signal, the cancer cell divides more slowly or stops growing.

SAFETY WATCH

Small increased risk of blood clots in the legs or lungs—call your doctor if you have sudden leg swelling, chest pain, or trouble breathing. · Can thicken the lining of the uterus (endometrium) and slightly raise the risk of uterine cancer—report any unusual vaginal bleeding. · May cause hot flashes, mood changes, or vaginal dryness. · Avoid pregnancy while taking tamoxifen—it can harm a developing baby.

Anastrozole, Letrozole, or Exemestane (aromatase inhibitors, or AIs) · Aromatase inhibitor

Stops the body from making estrogen after menopause. After menopause, the ovaries stop making estrogen, but fat tissue, muscles, and the adrenal glands still make small amounts using an enzyme (a chemical helper) called aromatase. AIs block aromatase, so very little estrogen gets made. Without estrogen, hormone-receptor-positive breast cancer cells can't get the 'grow' signal.

1. After menopause, the enzyme aromatase in fat and other tissues converts androgens (male-type hormones everyone has) into estrogen.
2. The AI drug blocks aromatase so it can't do this conversion.
3. Estrogen levels in the blood drop very low.
4. Hormone-receptor-positive breast cancer cells can't get enough estrogen to grow.

SAFETY WATCH

Can weaken bones over time (osteoporosis) because estrogen helps keep bones strong—your doctor may check bone density and recommend calcium, vitamin D, or bone-protecting medicine. · May cause joint pain or stiffness, especially in the hands and knees. · Can raise cholesterol slightly. · Does NOT increase risk of uterine cancer or blood clots like tamoxifen does.

Palbociclib, Ribociclib, or Abemaciclib (CDK4/6 inhibitors) · CDK4/6 inhibitor

Slows down the cancer cell's copying machine. Cells copy themselves by moving through a cycle (like a factory assembly line). Two proteins called CDK4 and CDK6 push the cell forward through the cycle. These drugs block CDK4 and CDK6, so the cancer cell gets stuck and can't divide. Used together with hormone therapy (tamoxifen or an AI) when hormone-receptor-positive breast cancer has spread to other parts of the body or come back.

1. CDK4 and CDK6 proteins push the cancer cell from the resting phase (G1) into the copying phase (S phase), where DNA is copied.

2. The CDK4/6 inhibitor drug blocks these proteins.
3. The cancer cell gets stuck in G1 and can't move forward to copy its DNA.
4. The cell stops dividing and eventually dies or stays dormant.

SAFETY WATCH

Lowers white blood cell counts (neutropenia), which can make infections more likely—your doctor will check blood counts regularly. · May cause diarrhea, nausea, or fatigue. · Abemaciclib can cause more diarrhea than the other two; take anti-diarrhea medicine as directed. · Can harm a developing baby—avoid pregnancy.

Trastuzumab (Herceptin) · HER2-targeted monoclonal antibody

Sticks to a protein called HER2 on the surface of cancer cells. About 1 in 5 breast cancers make too much HER2, which sends strong 'grow and divide' signals. Trastuzumab is an antibody (a guided missile made of protein) that finds HER2, blocks its signal, and tags the cancer cell so the immune system can attack it.

1. Trastuzumab is infused into a vein and travels through the bloodstream.
2. It finds and locks onto HER2 proteins sticking out of cancer cells.
3. Blocking HER2 stops the 'grow' signal inside the cell.
4. The antibody also marks the cell so immune cells (like natural killer cells) recognize and destroy it.

SAFETY WATCH

Can weaken the heart muscle (cardiomyopathy)—your doctor will check your heart function (echocardiogram or MUGA scan) before and during treatment. · Stop the drug if you develop shortness of breath, swelling in the legs, or very fast heartbeat. · First infusion may cause fever, chills, or allergic reaction—you'll be watched closely. · Avoid pregnancy—can harm the developing baby's kidneys and lungs.

Pertuzumab (Perjeta) · HER2-targeted monoclonal antibody (different binding site than trastuzumab)

Another antibody that sticks to HER2, but at a different spot than trastuzumab. HER2 proteins can pair up with each other or with related proteins to send even stronger 'grow' signals. Pertuzumab blocks these pairings (dimerization), cutting off another growth pathway. Used together with trastuzumab and chemotherapy for HER2-positive breast cancer—the two antibodies work as a team and are stronger together.

1. Pertuzumab binds to the HER2 protein on the cancer cell surface.

2. It prevents HER2 from pairing up (dimerizing) with other HER2 molecules or related receptors like HER3.
3. Without these pairs, the cell can't send 'grow' signals as strongly.
4. The cancer cell divides more slowly or stops growing.

SAFETY WATCH

Can weaken the heart, especially when combined with trastuzumab—heart function is monitored. · May cause diarrhea, rash, or low white blood cell counts (when given with chemotherapy). · First infusion may cause fever or chills. · Can cause severe harm to a developing baby—do not use during pregnancy.

Ado-trastuzumab emtansine (T-DM1, Kadcyla) · Antibody-drug conjugate (HER2-targeted)

A smart bomb: trastuzumab (the HER2 antibody) is chemically linked to a powerful chemotherapy drug called emtansine (DM1). The antibody delivers the chemo directly into HER2-positive cancer cells. Once inside, the chemo is released and kills the cell. Healthy cells are mostly spared because they don't have HER2. Used when HER2-positive breast cancer has spread and other treatments have stopped working.

1. T-DM1 travels through the blood and finds HER2 on cancer cells.
2. The cancer cell pulls the entire T-DM1 molecule inside (internalization).
3. Inside the cell, enzymes break the link between trastuzumab and emtansine.
4. Emtansine (the chemo) attaches to microtubules (the cell's scaffolding) and stops the cell from dividing, killing it.

SAFETY WATCH

Can damage the liver—your doctor will check liver tests regularly. · Can lower platelet counts (cells that help blood clot), raising the risk of bleeding or bruising. · May cause fatigue, nausea, or muscle pain. · Can weaken the heart—heart function is monitored. · Can harm lung tissue (rare)—report new cough or trouble breathing.

Fam-trastuzumab deruxtecan (T-DXd, Enhertu) · Antibody-drug conjugate (HER2-targeted, newer generation)

Similar to T-DM1 but carries a different, more powerful chemo payload (deruxtecan) and delivers more drug molecules per antibody. The trastuzumab part finds HER2-positive cancer cells, the cell pulls it inside, and the chemo is released to kill the cell. Some of the drug can

leak out and kill nearby cancer cells even if they have less HER2 (bystander effect). Used for HER2-positive breast cancer that has spread and is no longer responding to other treatments.

1. T-DXd binds to HER2 on the cancer cell surface.
2. The cell pulls T-DXd inside.
3. The link between antibody and chemo breaks, releasing deruxtecan.
4. Deruxtecan damages the cancer cell's DNA, stopping division and killing the cell.
5. Some deruxtecan leaks out and kills neighboring cancer cells.

SAFETY WATCH

Can cause serious lung inflammation (interstitial lung disease or pneumonitis)—report any new cough, shortness of breath, or fever immediately. · May cause nausea, vomiting, or diarrhea. · Can lower white blood cell counts, raising infection risk. · Can harm a developing baby—avoid pregnancy.

Pembrolizumab (Keytruda) · PD-1 immune checkpoint inhibitor

Wakes up the immune system so it can see and attack cancer cells. Cancer cells often wear a 'don't eat me' disguise by activating a checkpoint protein called PD-1 on immune T cells, which puts the T cells to sleep. Pembrolizumab blocks PD-1, so the T cells stay awake and kill cancer cells. Used in combination with chemotherapy for triple-negative breast cancer (cancer with no estrogen, progesterone, or HER2 receptors) that has spread or come back, and the tumor tests positive for PD-L1 (a marker showing the cancer is using this disguise).

1. Cancer cells make a protein called PD-L1 that sticks to PD-1 on T cells.
2. This PD-1/PD-L1 handshake tells the T cell to shut down and not attack.
3. Pembrolizumab blocks PD-1, so the handshake can't happen.
4. The T cell stays active, recognizes the cancer cell as foreign, and kills it.

SAFETY WATCH

Can cause the immune system to attack normal organs (immune-related side effects)—most commonly the lungs (pneumonitis), colon (colitis), liver (hepatitis), or thyroid and pituitary glands. · Report new cough, diarrhea, belly pain, extreme fatigue, or vision changes right away. · Steroid medicines may be needed to calm the immune system if side effects occur. · Infusion reactions (fever, chills, rash) can happen during or after the IV.

Olaparib or Talazoparib (PARP inhibitors) · PARP inhibitor

Stops cancer cells from repairing breaks in their DNA. Cells use an enzyme called PARP to fix small DNA breaks. If you have a BRCA1 or BRCA2 gene mutation (inherited or in the tumor),

your cells already can't fix big DNA breaks well. PARP inhibitors block the repair of small breaks too, so the cancer cell piles up so much broken DNA that it dies. Normal cells (with working BRCA) can still fix DNA other ways, so they survive better. Used for HER2-negative breast cancer in people with a BRCA mutation, especially after chemotherapy or when cancer has spread.

1. PARP enzyme normally fixes single-strand breaks in DNA.
2. The PARP inhibitor drug blocks PARP.
3. Single-strand breaks pile up and turn into double-strand breaks (worse damage).
4. In a cell with a BRCA mutation, the backup repair system is broken, so the damage can't be fixed.
5. The cancer cell accumulates too much DNA damage and dies.

SAFETY WATCH

Can lower red blood cell counts (anemia), causing fatigue—blood counts are monitored. · May cause nausea, vomiting, or diarrhea. · Small risk of developing a new blood cancer (myelodysplastic syndrome or leukemia) after long-term use—rare but serious. · Can harm a developing baby—use effective birth control.

Paclitaxel, Docetaxel, or Albumin-bound paclitaxel (taxanes) · Taxane chemotherapy

Stops cancer cells from dividing by freezing their internal scaffolding. Cells have a skeleton made of tiny tubes called microtubules that pull chromosomes apart when the cell divides. Taxanes glue the microtubules together so they can't move, and the cell gets stuck in the middle of division and dies. Used in many breast cancer treatment plans, especially triple-negative and HER2-positive cancers, often combined with other drugs.

1. Paclitaxel or docetaxel enters dividing cells.
2. It binds to microtubules and stabilizes them (normally they need to grow and shrink).
3. The cell tries to divide, but the microtubules are frozen and can't pull the chromosomes apart.
4. The cell is stuck in mitosis (division phase) and triggers its own death program (apoptosis).

SAFETY WATCH

Lowers white blood cell counts, raising infection risk—call your doctor if you have fever over 100.4°F (38°C). · Causes hair loss (temporary; hair grows back after treatment ends). · Can damage nerves (peripheral neuropathy), causing tingling, numbness, or pain in hands and feet—may be permanent if severe. · Allergic reactions can happen during infusion—you'll get pre-medications (steroids, antihistamines) to prevent this. · Albumin-bound paclitaxel (nab-paclitaxel) has less allergic reaction risk but still causes neuropathy.

Doxorubicin or Epirubicin (anthracyclines) · Anthracycline chemotherapy

Damages the DNA inside cancer cells so they can't copy it and divide. Doxorubicin slips between the rungs of the DNA ladder and also blocks an enzyme (topoisomerase II) that unwinds DNA for copying. It also makes toxic oxygen molecules (free radicals) that break DNA strands. Used in combination regimens for many breast cancers, especially aggressive or high-risk cancers.

1. Doxorubicin enters the cell and moves into the nucleus.
2. It slips between DNA base pairs (intercalation), bending and weakening the DNA.
3. It blocks topoisomerase II, an enzyme that cuts and reseals DNA so it can unwind for copying.
4. DNA breaks accumulate, and the cell can't repair them all.
5. The cell dies.

SAFETY WATCH

Can weaken the heart muscle (cardiomyopathy), especially at high cumulative doses—heart function is monitored with echocardiograms. · Turns urine red or orange for 1–2 days after infusion (harmless, not blood). · Lowers blood counts, raising risk of infection, anemia, and bleeding. · Causes hair loss (temporary). · Small risk of leukemia years later if total lifetime dose is very high.

Cyclophosphamide · Alkylating agent chemotherapy

Adds chemical anchors (alkyl groups) onto DNA strands, cross-linking them so the cell can't pull them apart to copy DNA. The cell tries to divide, realizes its DNA is glued together, and dies. Often combined with doxorubicin (AC regimen) or docetaxel (TC regimen) for breast cancer.

1. Cyclophosphamide is activated in the liver into its active form.
2. The active drug enters cells and binds to DNA.
3. It creates cross-links between the two DNA strands, like stapling pages together.

4. The cell can't unzip its DNA to copy it.
5. The cell dies when it tries to divide.

SAFETY WATCH

Can irritate the bladder and cause blood in the urine (hemorrhagic cystitis)—drink lots of water and urinate frequently; sometimes a protective drug (mesna) is given. · Lowers white blood cell counts, raising infection risk. · Can cause nausea—anti-nausea medicines are given. · May stop menstrual periods temporarily or permanently (depending on age and dose). · Small increased risk of bladder cancer or leukemia years later with high cumulative doses.

Carboplatin or Cisplatin (platinum-based chemotherapy) · Platinum agent chemotherapy

Sticks to DNA and cross-links it, similar to cyclophosphamide but using platinum instead of alkyl groups. The cross-links stop DNA from being copied or read, so the cell can't divide. Often used in triple-negative breast cancer, especially if there's a BRCA mutation (these cancers are more sensitive to DNA-damaging drugs).

1. Carboplatin or cisplatin enters the cell.
2. Platinum atoms bind to DNA at specific sites (guanine bases).
3. The platinum creates cross-links within one DNA strand or between two strands.
4. DNA can't be copied or repaired properly.
5. The cell stops dividing and dies.

SAFETY WATCH

Carboplatin: Lowers platelet and white blood cell counts more than cisplatin; watch for easy bruising or infection. · Cisplatin: Can damage kidneys—lots of IV fluids are given before and after; can cause severe nausea (needs strong anti-nausea meds); can damage hearing (ototoxicity) or nerves (neuropathy). · Both can cause tingling or numbness in hands and feet. · Carboplatin is generally better tolerated than cisplatin.

Capecitabine or 5-Fluorouracil (5-FU) · Antimetabolite chemotherapy (fluoropyrimidine)

Tricks the cell into using a fake building block for DNA and RNA. Capecitabine (a pill) turns into 5-FU inside the body. 5-FU looks like a normal base (thymine or uracil) but when the cell

tries to use it to build new DNA or RNA, it doesn't work right, and the cell can't copy itself. Sometimes used for advanced or metastatic breast cancer.

1. Capecitabine is absorbed and converted to 5-FU (often more in tumor tissue, so some selectivity).
2. 5-FU gets incorporated into RNA and DNA as a false building block.
3. It also blocks thymidylate synthase, stopping the cell from making real thymine (a DNA letter).
4. Without enough thymine, DNA copying fails and the cell dies.

SAFETY WATCH

Hand-foot syndrome (palmar-plantar erythrodysesthesia): redness, peeling, pain on palms and soles—moisturize and report early. · Diarrhea—can be severe; take anti-diarrhea medicine and stay hydrated. · Lowers white blood cell counts. · Mouth sores (mucositis). · Rare but serious: severe reaction in people with a genetic deficiency of the enzyme DPD (dihydropyrimidine dehydrogenase)—can cause life-threatening toxicity.

Zoledronic acid or Denosumab (bone-targeted agents) · Bisphosphonate (zoledronic acid) or RANKL inhibitor (denosumab)

Protects bones from cancer-related damage. Breast cancer that spreads to bones can weaken them by activating bone-eating cells (osteoclasts). Zoledronic acid sticks to bone and poisons osteoclasts when they try to break down bone. Denosumab blocks RANKL, a signal that tells osteoclasts to activate. Both reduce fractures and bone pain when breast cancer has spread to bones. Zoledronic acid is also sometimes given to postmenopausal women on aromatase inhibitors to prevent bone thinning (osteoporosis).

1. Zoledronic acid: Infused into a vein, travels to bone, and gets absorbed into the bone matrix. When osteoclasts break down bone, they take up zoledronic acid and die.
2. Denosumab: Injected under the skin, binds to RANKL (a protein signal), preventing it from activating osteoclasts. Without the signal, osteoclasts don't form or work as much.
3. In both cases, bone breakdown slows, bones stay stronger, and fracture risk drops.

SAFETY WATCH

Both can cause low calcium in the blood (hypocalcemia)—take calcium and vitamin D supplements as directed. · Rare but serious: osteonecrosis of the jaw (bone death in the jaw, especially after dental work)—get a dental check-up before starting and avoid invasive dental procedures if possible; tell your dentist you're on these drugs. · Zoledronic acid can cause flu-like symptoms (fever, muscle aches) after the first infusion, usually milder after that. · Zoledronic acid can harm the kidneys if infused too fast—kidney function is checked before each dose. · Denosumab can cause bone pain or muscle aches.

Fulvestrant · Selective estrogen receptor degrader (SERD)

Destroys estrogen receptors on cancer cells. Unlike tamoxifen (which blocks the receptor), fulvestrant binds to the receptor and causes the cell to break it down and throw it away. With no receptors left, estrogen has nowhere to attach and can't send 'grow' signals. Given as a monthly injection into the muscle. Used for hormone-receptor-positive breast cancer that has spread, especially after tamoxifen or aromatase inhibitors stop working.

1. Fulvestrant is injected and slowly released into the bloodstream.
2. It enters breast cancer cells and binds tightly to estrogen receptors.
3. The receptor changes shape and is marked for destruction.
4. The cell breaks down the receptor, so there are fewer receptors available.
5. Without receptors, estrogen can't signal the cell to grow.

SAFETY WATCH

Injection site reactions (pain, swelling at the injection site in the buttock). · Can cause hot flashes, nausea, or fatigue. · May increase liver enzymes—monitored with blood tests. · Generally fewer serious side effects than chemotherapy.

Everolimus · mTOR inhibitor

Blocks a growth signal inside cancer cells. mTOR is a protein that acts like a master switch, telling the cell to grow, make new proteins, and divide. Some hormone-receptor-positive breast cancers become resistant to hormone therapy by turning on mTOR to bypass the estrogen blockade. Everolimus blocks mTOR, turning off these escape signals. Used in combination with an aromatase inhibitor (like exemestane) when hormone therapy alone stops working in postmenopausal women with advanced hormone-receptor-positive, HER2-negative breast cancer.

1. Everolimus enters the cell and binds to a protein called FKBP12.
2. This complex blocks mTOR (a kinase enzyme).

3. mTOR can no longer send signals to make proteins and push the cell through the growth cycle.
4. The cancer cell stops growing and dividing.

SAFETY WATCH

Mouth sores (stomatitis)—very common; use alcohol-free mouthwash and report painful sores. · Can cause lung inflammation (non-infectious pneumonitis)—report new cough or shortness of breath. · Raises blood sugar—may worsen diabetes. · Lowers white blood cell counts, raising infection risk. · Raises cholesterol and triglycerides—monitored with blood tests. · Can cause diarrhea, rash, or fatigue.

Alpelisib · PI3K inhibitor

Blocks a growth signal protein called PI3K (phosphoinositide 3-kinase) inside cancer cells. Some hormone-receptor-positive breast cancers develop a mutation in the PIK3CA gene, which makes PI3K overactive, allowing the cancer to ignore hormone therapy. Alpelisib specifically blocks this overactive PI3K, cutting off the growth signal. Used in combination with fulvestrant for postmenopausal women or men with hormone-receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer after hormone therapy stops working. A genetic test of the tumor is required to find the PIK3CA mutation.

1. Alpelisib enters cells and binds to the PI3K alpha enzyme.
2. It blocks PI3K from activating downstream signals (like AKT and mTOR) that tell the cell to grow and survive.
3. Without these signals, the cancer cell stops dividing.

SAFETY WATCH

Raises blood sugar (hyperglycemia)—very common and sometimes severe; blood sugar is checked regularly. You may need diabetes medicine or to adjust existing diabetes treatment. · Can cause severe rash. · Can cause severe diarrhea—treated with anti-diarrhea medicine; report if persistent. · Can affect kidney function—monitored with blood tests. · May cause nausea or fatigue.

Neratinib · HER2-targeted tyrosine kinase inhibitor (TKI)

Blocks the signal inside HER2-positive cancer cells. Unlike trastuzumab (which sticks to HER2 from the outside), neratinib is a small pill that gets into the cell and blocks the HER2 protein from the inside, stopping it from sending 'grow' signals. It also blocks related proteins (EGFR,

HER4). Used after a full year of trastuzumab treatment to lower the chance of cancer coming back in early-stage HER2-positive breast cancer.

1. Neratinib enters the cell.
2. It permanently binds to the inside part of the HER2 receptor (the tyrosine kinase domain).
3. HER2 can no longer send 'grow' signals (phosphorylation is blocked).
4. The cancer cell stops dividing.

SAFETY WATCH

Severe diarrhea in most patients—start anti-diarrhea medicine (loperamide) from day 1 and follow your doctor's schedule closely. Diarrhea usually improves after the first month. · Can cause nausea, belly pain, or vomiting. · Can cause mouth sores or rash. · Can harm a developing baby—use effective birth control.

Tucatinib · HER2-targeted tyrosine kinase inhibitor (TKI), highly selective

A pill that blocks HER2 from the inside, similar to neratinib but more selective for HER2 (less effect on EGFR, so fewer side effects). It can cross into the brain better than antibodies like trastuzumab, making it useful when HER2-positive breast cancer spreads to the brain. Used in combination with trastuzumab and capecitabine for advanced HER2-positive breast cancer that has been treated before.

1. Tucatinib enters the cancer cell.
2. It binds to the HER2 tyrosine kinase domain (the signaling switch).
3. HER2 can no longer turn on growth signals.
4. The cancer cell stops dividing.

SAFETY WATCH

Can cause diarrhea (less severe than neratinib, but still common). · Can raise liver enzymes—liver tests are monitored. · May cause nausea or fatigue. · Can harm a developing baby—use birth control.

Lapatinib · HER2 and EGFR dual tyrosine kinase inhibitor

A pill that blocks both HER2 and EGFR (a related growth signal protein) from the inside of the cell. Used when HER2-positive breast cancer has spread and stopped responding to trastuzumab. Often combined with capecitabine or an aromatase inhibitor (if the cancer is also hormone-receptor-positive). Newer drugs (neratinib, tucatinib) are often preferred now.

1. Lapatinib enters the cell.
2. It blocks the tyrosine kinase parts of both HER2 and EGFR.

3. Growth signals from both receptors are turned off.
4. The cancer cell stops dividing.

SAFETY WATCH

Can cause diarrhea—take anti-diarrhea medicine as directed. · Can cause liver damage—liver tests are checked regularly. · Can weaken the heart—heart function is monitored. · May cause rash, nausea, or fatigue. · Can harm a developing baby.

Sacituzumab govitecan · Antibody-drug conjugate (Trop-2-targeted)

A smart bomb that targets a protein called Trop-2, which is found on many cancer cells (not just breast cancer). The antibody part finds Trop-2, the cancer cell pulls the drug inside, and a chemo payload (a topoisomerase inhibitor like irinotecan) is released to kill the cell. Used for triple-negative breast cancer that has spread and been treated with at least two other therapies, and for hormone-receptor-positive, HER2-negative breast cancer after hormone therapy and other treatments stop working.

1. Sacituzumab govitecan binds to Trop-2 on the cancer cell surface.
2. The cell pulls the antibody-drug conjugate inside.
3. The chemo (SN-38, the active form of irinotecan) is released.
4. SN-38 blocks topoisomerase I (an enzyme that helps DNA unwind), causing DNA breaks.
5. The cancer cell can't repair the damage and dies.

SAFETY WATCH

Severe diarrhea—can be life-threatening; take anti-diarrhea medicine at the first loose stool and call your doctor if it doesn't stop quickly. · Severe low white blood cell counts (neutropenia)—infection risk is high; your doctor may give a medicine (G-CSF) to boost white cells. · Nausea and vomiting—anti-nausea meds are given. · Hair loss. · People with a genetic variation (UGT1A1*28) break down the drug more slowly and have worse side effects—genetic testing may be done.

Red flags

- A hard lump that does not move and has irregular edges
- Skin dimpling, puckering, or orange-peel texture on the breast
- Nipple discharge that is bloody or clear and comes out on its own
- Sudden redness, warmth, and swelling of the breast (inflammatory breast cancer)
- Nipple turning inward or a new change in breast size or shape that does not go away

Nursing priorities

1. Assess bilateral breasts, lymph nodes under arms and above collarbones, and document size, location, and characteristics of any lumps using clock-face method and centimeters — Lymph node involvement (cancer spread to nodes) changes staging from early to advanced and determines whether sentinel node biopsy (remove 1-3 nodes) or axillary dissection (remove 10-40 nodes) is needed, and accurate documentation helps surgeons plan incision location
2. Monitor for signs of inflammatory breast cancer: breast warmth, redness covering one-third or more of breast, peau d'orange (orange-peel skin dimpling), and rapid onset over weeks, and escalate immediately if present — Inflammatory breast cancer blocks dermal lymphatics (tiny drainage vessels in skin) causing fluid backup and skin changes, grows fast with high risk of metastasis (spread), and needs urgent chemotherapy first instead of surgery, so delay worsens survival
3. Obtain complete medication history including hormone replacement therapy, oral contraceptives, and herbal supplements, and note duration of use — Estrogen exposure from hormones stimulates growth of ER-positive (estrogen-receptor-positive) tumors, must be stopped before hormone therapy like tamoxifen works, and some supplements like black cohosh interfere with treatment effectiveness
4. Teach breast self-exam technique and provide written instructions on monthly timing (one week after period starts) and what changes to report immediately — Seventy percent of breast cancers are found by women themselves, early detection of recurrence (cancer coming back) improves survival, and regular self-exam helps women know their normal baseline so new changes are caught within weeks not months
5. Screen for anxiety, depression, and fear of disfigurement using validated tools, and offer referral to oncology social worker and support groups before treatment starts — Thirty to forty percent of breast cancer patients develop major depression or anxiety disorder which decreases treatment adherence (following the plan), suppresses immune function through cortisol elevation (stress hormone), and worsens outcomes and quality of life
6. Coordinate genetic counseling referral for patients under age 50, triple-negative or bilateral cancer, male breast cancer, or strong family history of breast or ovarian cancer — BRCA1 and BRCA2 mutations change surgical decisions because these patients have 40-80% lifetime risk of second breast cancer and may choose bilateral mastectomy (remove both breasts), plus family members need testing and increased surveillance
7. Document reproductive history including age at first period, age at first live birth, breastfeeding duration, and number of pregnancies — Early menarche before age 12 and first pregnancy after age 30 increase estrogen exposure years and risk of hormone-receptor-positive cancers, while breastfeeding reduces risk, and this history predicts tumor biology and response to hormone therapy

8. Prepare patient for core needle biopsy or surgical biopsy by explaining that tissue must be tested for estrogen receptor (ER), progesterone receptor (PR), and HER2 protein status because results determine entire treatment plan — Receptor status divides breast cancer into four molecular subtypes with completely different treatments: ER/PR-positive gets hormone therapy, HER2-positive gets trastuzumab, triple-negative gets chemotherapy only, so treatment cannot start until pathology results return in 3-5 days

Sources

- NCCN Clinical Practice Guidelines in Oncology: Breast Cancer 2024
- American Cancer Society Breast Cancer Guidelines
- U.S. Preventive Services Task Force (USPSTF) Breast Cancer Screening Recommendation 2024
- National Cancer Institute (NCI) PDQ Breast Cancer Treatment

Last reviewed: 2026-07-07